L3VLUP
ProSign in

TARS in the 13F filings

Tarsus Pharmaceuticals Inc · CUSIP 87650L103

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2024
the date the book describes
Filed
14 Nov 2024
latest of these filings; the earliest 12 Nov 2024
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q2 2024 and Q3 2024; 2 listed it in both
Shares listed
1,894,523
combined, among listed positions
Reported value
$62m
combined, at the quarter end

Among the 94 comparable managers: 5 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing TARS in Q3 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
ExodusPoint Capital Management LP883,043$29m0.18%Added+212,58412 Nov 2024 (the filing on sec.gov)
Artisan Partners LP709,018$23munder 0.1%Added+81,44012 Nov 2024 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC187,513$6.2munder 0.1%Addedn.a.14 Nov 2024 (the filing on sec.gov)
Woodline Partners LP71,569$2.4munder 0.1%Newnew14 Nov 2024 (the filing on sec.gov)
Brevan Howard Capital Management LP43,380$1.4munder 0.1%Newnew14 Nov 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2024 to Q3 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (2)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 4 in Q2 2026

Tracked managers listing it, at least.

0246Q1 2021Q4 2023Q2 2024Q4 2024Q2 2025Q4 2025Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
TARS by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20211$397kn.a.n.a.
Q3 20232$14mn.a.n.a.
Q4 20232$13m02
Q1 20242$31m11
Q2 20242$35m20
Q3 20245$62m50
Q4 20244$46m22
Q1 20251$31m01
Q2 20253$98m21
Q3 20253$122m11
Q4 20254$202m1810
Q1 20264$184m1414
Q2 20264$201m1612

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

TARS and GILD →TARS and AMGN →TARS and ARGX →Choose a stock to compare with TARS →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own TARS, latest filings →Back to the 13F Explorer →